Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$25.06 USD
+1.18 (4.94%)
Updated May 2, 2024 04:00 PM ET
After-Market: $25.08 +0.02 (0.08%) 4:52 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CORT 25.06 +1.18(4.94%)
Will CORT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CORT
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for April 17th
Other News for CORT
Corcept Therapeutics (CORT) Gets a Buy from Truist Financial
Corcept Therapeutics price target raised by $2 at H.C. Wainwright, here's why
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
Corcept: Q1 Earnings Snapshot